← Volver a la portada
Américas · Mercados regionales · BNN Bloomberg

Conavi Medical launches OCTIV™ in the U.S. with first commercial placement and clinical cases

Publicado por BNN Bloomberg · Canadá hace 16 min
Conavi Medical launches OCTIV™ in the U.S. with first commercial placement and clinical cases
BNN Bloomberg

Resumen detallado

Tom Looby, President and CEO, and Amandeep Thind, CTO, of Conavi Medical Corp., discuss the U.S. launch of OCTIV™, the Toronto-based company’s coronary imaging system that puts…

Tom Looby, President and CEO, and Amandeep Thind, CTO, of Conavi Medical Corp. (TSXV: CNVI | OTCQB: CNVIF), discuss the U.S. launch of OCTIV™, the Toronto-based company’s coronary imaging system that puts two complementary imaging technologies into a single catheter. With stronger guideline support for imaging-guided coronary procedures and the first U.S. clinical cases completed, Conavi is taking a significant step forward in its targeted commercial rollout.

Intravascular ultrasound (IVUS) and optical coherence tomography (OCT) are established coronary imaging tools, but products on the market typically offer one or the other. Looby explains that cost and set-up time often lead doctors to choose a single modality. IVUS provides imaging depth, while OCT offers high-resolution detail. Conavi’s OCTIV system brings both modalities into one catheter.

“We are launching into a hot market right now,” says Looby. The market backdrop includes stronger guideline support for intravascular imaging. In the U.S., the 2025 acute coronary syndromes guideline gives IVUS or OCT a Class 1, Level A recommendation for procedural guidance in patients undergoing coronary stent implantation in the left main artery or in complex lesions. A 2024 meta-analysis published in The Lancet found a 45% relative reduction in the risk of cardiac death with intravascular imaging-guided procedures compared with angiography guidance alone. That evidence relates to IVUS- or OCT-guided procedures generally.

On November 2, 2026, Conavi announced its first U.S. commercial placement and completed clinical cases with OCTIV. The milestone brings the company’s next-generation, FDA-cleared hybrid imaging system into clinical use in the U.S. By combining IVUS and OCT in one catheter, OCTIV gives physicians complementary views of coronary anatomy within a single workflow. Conavi is now focused on supporting clinical use at its first site and advancing placements at additional U.S. institutions.

Inicio del artículo, extracto de BNN Bloomberg. Para leer el resto, abra el artículo en el sitio del medio.

Leer el artículo completo en BNN Bloomberg Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.bnnbloomberg.ca)

También te puede interesar